MannKind Corp. (NASDAQ:MNKD) released its earnings data on Tuesday. The company reported ($0.16) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.14) by $0.02, American Banking and Market News reports. MannKind Corporation (NASDAQ:MNKD) stock opened at $5.98 in last trading session, and closed at $5.96, trading in the range of $5.81 – $6.09. The stock showed a positive weekly performance of 5.86%.
Shares of Johnson & Johnson (NYSE:JNJ) saw unusually large options trading activity on Thursday. Traders acquired 13,795 put options on the stock, AmericanBankingNews.com reports. This represents an increase of 126% compared to the average daily volume of 6,104 put options. Johnson & Johnson (NYSE:JNJ) shares closed at $92.38 on last trade day, by gaining 0.81%. Stock 52 week range is $75.50 – $95.99. Company’s market capitalization is $260.64 billion.
Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) was a big mover last session, as its shares rose over 24% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the trend for the healthcare company, as the stock is now trading above the volatile price range of $4.31 to $5.34. Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) stock decreased -3.41% and finished the last session at $5.95. The EPS of the stock remained -0.20. Company’s market capitalization is $466.68 million.
Raptor Pharmaceutical Corp. (NASDAQ:RPTP) announced top line results from a planned 18 month analysis of an ongoing 3 year Phase 2/3 clinical trial of RP103 (delayed-release cysteamine) for the potential treatment of Huntington’s disease (HD) in collaboration with the Centre Hospitalier Universitaire d’Angers (CHU d’Angers). A total of 96 patients with HD were randomized to treatment with RP103 or placebo. Eighty nine patients completed the initial 18 month phase. Analysis of all 96 patients enrolled in the trial showed a positive trend towards slower progression of Total Motor Score (TMS) in patients treated with RP103 vs. those patients on placebo, the primary endpoint of the study. TMS progression was 32% slower in patients treated with RP103 vs. those treated with placebo after 18 months treatment (4.51 vs. 6.68 respectively, p=0.19). In 66 patients not taking concurrent tetrabenazine, RP103 treatment resulted in a statistically significant slower progression in TMS vs. the placebo group (2.84 points vs. 6.78 respectively, p=0.03). Raptor Pharmaceutical Corp. (NASDAQ:RPTP) stock opened at $17.05 in last trading session and closed at $17.14. The 52 week range of the stock is $4.87 – $17.72 and the day range was $16.33 – $17.72.